Effect of myrrh extract on the liver of normal and bilharzially infected mice. An ultrastructural study.
In the present work, the efficacy of purified oloe-resin extract of myrrh derived from Commiphora molmol tree (commercially known as Mirazid) as a new, natural antischistosomal drug was investigated. The effect of myrrh on the ultrastructural profile of the non infected normal mice liver was also studied. Sixty male mice were used throughout this work and they were divided into 3 main groups (20 animals each): group I, non infected control animals, group II, infected animals and group III, infected animals treated with myrrh extract 8 weeks post infection (500 mg/kg body weight). The drug was given orally on an empty stomach after overnight fasting for five successive days. All animals were sacrificed after 12 weeks from the beginning of the experiment and small pieces of the liver were excised and prepared for ultrastructural study. The liver of the non infected animals which received myrrh extract (group IA) showed a more or less normal ultrastructural profile. Infected groups showed alterations of the ultrastructure of most of the hepatocytes with extensive intercellular fibrosis with abundant granulomas in the portal tract. In the infected treated group, most of the hepatocytes showed normal organelles with numerous microvilli extending into patent spaces of Disse. Marked reduction of granulomas in the portal areas and amelioration of intercellular fibrosis was also observed. On the basis of the observed results, it was concluded that myrrh extract has a promising antischistosomal non hepatotoxic activity.
Massoud
Ahmed M A
AM
Department of Tropical Medicine, Faculty of Medicine, Al-Azhar University, Nasr City.
El Ebiary
Faika H
FH
Abd El Salam
Nevert F
NF
D000818:Animals; D029744:Commiphora; D004195:Disease Models, Animal; D008099:Liver / Q000187:drug effects* / Q000469:parasitology / Q000648:ultrastructure; D008297:Male; D051379:Mice; D008517:Phytotherapy; D010936:Plant Extracts / Q000009:adverse effects / Q000494:pharmacology*; D011897:Random Allocation; D012552:Schistosomiasis / Q000188:drug therapy*; D012556:Schistosomicides / Q000009:adverse effects / Q000494:pharmacology*; D013729:Terpenes / Q000009:adverse effects / Q000494:pharmacology; D016896:Treatment Outcome
D010936:Plant Extracts; D012556:Schistosomicides; D013729:Terpenes; C014119:myrrh oil